Archna Bajaj

University of Pennsylvania

H指数:16

被引数:1,241

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Lowering cumulative LDL-C exposure: the case for early treatment

降低累积LDL-C暴露：早期治疗的必要性

European Heart Journal

IF35.6

2026-08-260

PRE

Real-world cardiovascular and safety outcomes associated with lipoprotein apheresis using the LIPOSORBER® LA-15 system in patients with atherosclerotic cardiovascular disease having elevated lipoprotein(a): A retrospective chart review study in the US

使用LIPOSORBER® LA-15系统进行脂蛋白吸附疗法在具有高脂蛋白(a)水平的动脉粥样硬化性心血管疾病患者中的真实世界心血管和安全结局：一项在美国进行的回顾性病历审查研究

American Journal of Preventive Cardiology

IF5.9

2026-08-220

Base editing and silencing of PCSK9 shows clinical promise in humans

PCSK9的碱基编辑和沉默在人类中显示出临床前景

Nature Reviews Cardiology

IF44.2

2026-04-270

PRE

Low-Density Lipoprotein Cholesterol Lowering and Risk of Major Adverse Cardiovascular Events in Primary Prevention Trials: A Meta-Analysis

低密度脂蛋白胆固醇降低与主要不良心血管事件风险：一项Meta分析

Journal of Clinical Lipidology

IF4.6

2026-02-130

OAAI

Lipoprotein(a) Testing in an Outpatient Cardiology Clinic: A Quality Improvement Initiative

在门诊心脏病诊所进行脂蛋白 (a) 检测: 一项质量改进计划

Journal of Clinical Lipidology

IF4.6

2026-01-270

OAAI

Gene therapy and genome editing for lipoprotein disorders

脂蛋白紊乱的基因治疗与基因组编辑

EUROPEAN HEART JOURNAL

IF35.6

2025-07-014

OAAI

Pelacarsen: Mechanism of action and Lp(a)-lowering effect

Pelacarsen：作用机制与Lp(a)降低效果

Journal of Clinical Lipidology

IF4.6

2025-06-160

PREAI

Obicetrapib lowers LDL-cholesterol by substantially increasing LDL-ApoB clearance rates in humans

Obicetrapib通过显著增加人类LDL-ApoB清除率来降低LDL-胆固醇。

Journal of Clinical Lipidology

IF4.6

2025-05-290

PRE

Real-world experience of inclisiran prescription at the University of Pennsylvania Health Systems

JOURNAL OF CLINICAL LIPIDOLOGY

IF4.6

2024-11-010

PRE

Attitudes and barriers to lipoprotein(a) testing: A survey of providers at the University of Pennsylvania Health System

JOURNAL OF CLINICAL LIPIDOLOGY

IF4.6

2024-09-013

PRE

A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practice

JOURNAL OF CLINICAL LIPIDOLOGY

IF4.6

2024-05-0170

PRE

Harnessing RNA Interference for Cholesterol Lowering: The Bench-to-Bedside Story of Inclisiran

JOURNAL OF THE AMERICAN HEART ASSOCIATION

IF5.3

2024-03-199

OAAI

Prevalence of Lipoprotein(a) Testing Among Patients With CAD: A 10-year Retrospective Analysis at The University of Pennsylvania Health Systems

CIRCULATION

IF38.6

2023-11-071

PRE

Recent advances in the management and implementation of care for familial hypercholesterolaemia

家族性高胆固醇血症的管理和实施的最新进展

PHARMACOLOGICAL RESEARCH

IF10.5

2023-08-016

OAAI

Lipoprotein(a) and the Risk for Recurrent Atherosclerotic Cardiovascular Events Among Adults With CKD: The Chronic Renal Insufficiency Cohort (CRIC) Study

KIDNEY MEDICINE

IF3.4

2023-07-014

OAAI

Feasibility and outcomes from using a commitment devices and text message reminders to increase adherence to time-restricted eating: A randomized trial

AMERICAN HEART JOURNAL

IF3.5

2023-04-016

PRE

From supravalvular to valvular aortic stenosis: are statins contributing to the phenotypic shift in homozygous familial hypercholesterolaemia?

EUROPEAN HEART JOURNAL

IF35.6

2022-07-137

PRE

A systematic review of the natural history and biomarkers of primary lecithin:cholesterol acyltransferase deficiency

JOURNAL OF LIPID RESEARCH

IF4.1

2022-03-0112

OAAI

Clinical Management of Hypertriglyceridemia in the Prevention of Cardiovascular Disease and Pancreatitis

CURRENT ATHEROSCLEROSIS REPORTS

IF5.2

2021-09-1333

OAAI

Implementation of a Machine-Learning Algorithm in the Electronic Health Record for Targeted Screening for Familial Hypercholesterolemia A Quality Improvement Study

CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES

IF6.7

2021-06-019

Archna Bajaj

个人简介

教育背景

工作经历

荣誉奖项

研究方向